Paratek Pharmaceuticals Inc
F:N4CN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jiangsu King's Luck Brewery Joint-Stock Co Ltd
SSE:603369
|
CN |
|
Z
|
Zhuhai CosMX Battery Co Ltd
SSE:688772
|
CN |
Paratek Pharmaceuticals Inc
Intangible Assets
Paratek Pharmaceuticals Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Paratek Pharmaceuticals Inc
F:N4CN
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Intangible Assets
$50.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Intangible Assets
$19.1B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
30%
|
|
|
Pfizer Inc
NYSE:PFE
|
Intangible Assets
$53.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Intangible Assets
$26.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Intangible Assets
$6.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
3%
|
|
Paratek Pharmaceuticals Inc
Glance View
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. The company is headquartered in Boston, Massachusetts and currently employs 207 full-time employees. The company went IPO on 2006-05-10. The firm is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The firm's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.
